Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from MedAdvisor Limited ( (AU:AHE) ).
Adheris Health Limited has reported that all resolutions put to shareholders at its Extraordinary General Meeting on 12 March 2026 were passed by the required majority via poll. Investors approved amendments to the company’s Long Term Incentive Plan and the issuance of FY26 employee incentive options to CEO and managing director John Ciccio, signalling strong shareholder backing for the current leadership and remuneration structure.
The voting outcomes, delivered in line with ASX governance and Corporations Act requirements, underscore continued investor support for Adheris Health’s strategic direction and its use of equity-based incentives to align management with long-term performance. This endorsement may strengthen the company’s position as it pursues growth in pharmacy-focused patient engagement across its extensive U.S. network.
The most recent analyst rating on (AU:AHE) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:AHE Stock Forecast page.
More about MedAdvisor Limited
Adheris Health Limited is a pharmacy-driven patient engagement company that delivers personalised solutions to simplify the medication journey. Leveraging its THRiV cloud-based, AI-enabled platform, it helps optimise pharmacy workflows and patient communication. The company works with more than 25,000 pharmacies across the U.S., reaching over half of the population.
Average Trading Volume: 597,675
Technical Sentiment Signal: Sell
Current Market Cap: A$14.65M
Find detailed analytics on AHE stock on TipRanks’ Stock Analysis page.